Physician

Kurt P Leuenberger, MD

According to 2025 Medicare claims, Kurt Leuenberger, MD (NPI: 1194765800) practices medical oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Hamilton, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY CARE INC (NPI: 1790778041; TIN: 311106418) and primary practice location at 45211-1108. Leuenberger is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Leuenberger's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 729 traditional Medicare patients, billed 156,520 HCPCS/CPT codes, and received $3,356,499 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,475 prescription claims across 422 beneficiaries totaling $7,720,368 in drug costs, led by Imbruvica (Ibrutinib). 2022 DME data shows 65 claims. Open Payments data shows 74 records totaling $5,022. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,274,327 to $7,720,368. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $19,621 to $1,355.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	963	225,775	$2,534,497
2016	1,034	292,949	$3,636,341
2017	1,071	195,246	$3,081,580
2018	973	183,716	$3,290,886
2019	889	207,337	$4,113,945
2020	807	223,366	$3,947,268
2021	815	177,017	$3,121,435
2022	811	142,950	$2,678,782
2023	729	170,580	$3,396,631
2024	729	156,520	$3,356,499

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	349	2,303	$1,274,327
2016	357	2,887	$2,170,564
2017	372	2,579	$2,245,222
2018	360	2,693	$2,959,261
2019	336	2,596	$3,410,661
2020	339	2,924	$3,726,323
2021	355	3,047	$4,451,124
2022	401	3,153	$5,134,920
2023	421	3,487	$6,293,671
2024	422	3,475	$7,720,368

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	79	430	$57,342
2016	70	592	$55,525
2017	53	375	$32,418
2018	35	329	$18,119
2019	N/R	234	$11,374
2020	N/R	217	$12,344
2021	N/R	84	$6,220
2022	N/R	65	$4,002
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	230	665	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	439	723	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	414	693	$12
80053	Blood test, comprehensive group of blood chemicals	233	676	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	398	1,250	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	83	2,337	$1,155,627
Cabometyx	Cabozantinib S-Malate	44	1,320	$1,119,680
Revlimid	Lenalidomide	58	1,458	$976,942
Lenalidomide	Lenalidomide	47	1,246	$687,360
Xtandi	Enzalutamide	36	1,320	$484,042

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	74	$5,022	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kurt P. Leuenberger, MD?

Tedicare shows public-source Medicare data for Kurt P. Leuenberger, MD (NPI 1194765800), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kurt P. Leuenberger, MD have ACO affiliation data?

Kurt P. Leuenberger, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Kurt P. Leuenberger, MD?

Kurt P. Leuenberger, MD is linked to ONCOLOGY HEMATOLOGY CARE INC (billing NPI 1790778041) in the available physician profile data.

Does Kurt P. Leuenberger, MD have Open Payments data?

Kurt P. Leuenberger, MD has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.